The National Heart, Lung, and Blood Institute (NHLBI) invites applications for research grants to identify novel biomarkers
of chronic obstructive pulmonary disease (COPD).
Cystatin C-A Biomarker
of Risk in Chronic Kidney Disease
com/research/c576bc/the_state_of_bioma) has announced the addition of the "The State of Biomarkers
in Clinical Development" report to their offering.
should allow better measurements of exposure or earlier identification of health effects.
In-depth understanding of biomarker
deal trends since 2000
Much of the Arctic conference focused on biomarkers
under development to measure exposures to pollutants, their effects, and variations in people's susceptibility to such effects.
20 (Regulatory perspective for biomarker
qualification from US-FDA (Federico Goodsaid)
This report contains over 700 links to online copies of actual biomarker
deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Biochemistry of Cancer Cells Carcinogen Metabolism Causes of Cancer Growth Environmental Factors, DNA, RNA Cellular Oncogenes Tumor Suppressor Genes History of Cancer Cancer Types Biomarker
Examples New Developments Total Market Size and Forecast Cancer Biomarker
Market by Geographical Region Competitor Summary CHAPTER FIVE: BIOMARKERS IN CARDIOVASCULAR DISEASE AND BLOOD DISORDERS Overview The Cardiovascular System Heart Circulatory System Cardiac Cycle Coronary Circulation Cardiac Myocytes Molecular Contraction Cardiovascular And Blood Diseases Ischemic Heart Disease
As the field of biomarker
research matures, patient stratification will become routine.
The high growth of biomarker
market is boosted by the demand from the baby boomer generation in the U.
There is a real desire within our industry for a better understanding of how biomarkers
are being incorporated into clinical trials.
The report suggests investment decisions in biomarker
based drug research by providing information on valid biomarkers
, pipelines, case studies, competitive landscape, geographical dominance, mergers and acquisitions and market potential.
) has announced the addition of Frost & Sullivan's new report "European Biomarker
Analysis Market" to their offering.
markets are estimated from 2008 to 2018 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics.